Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4708 | rhTPO Wiki | 0.82 |
| drug3393 | Rosuvastatin (Inhibitor arm) Wiki | 0.58 |
| drug3394 | Rosuvastatin (Placebo arm) Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013921 | Thrombocytopenia NIH | 0.82 |
| D016553 | Purpura, Thrombocytopenic, Idiopathic NIH | 0.82 |
| D003139 | Common Cold NIH | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001873 | Thrombocytopenia HPO | 0.82 |
| HP:0001973 | Autoimmune thrombocytopenia HPO | 0.82 |
Navigate: Correlations HPO
There are 3 clinical trials
This is a prospective, multicenter, randomized, open-label study to investigate the efficacy and safety of eltrombopag plus recombinant human thrombopoietin (rhTPO) versus eltrombopag as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) during the COVID-19 pandemic.
Description: A complete response (CR) was defined as a sustained (≥ 3 months) platelet count ≥ 100×10^9/L.
Measure: Complete response Time: 6 monthsDescription: A response (R) was defined as a sustained (≥ 3 months) platelet count ≥ 30×10^9/L without recurrence of thrombocytopenia.
Measure: Response Time: 6 monthsDescription: No response (NR) was defined as platelet count < 30 × 10^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart.
Measure: No response Time: 6 monthsDescription: A relapses was defined as platelet count falls below 30×10^9/L or bleeding accrues after achieving R or CR.
Measure: Relapses Time: 6 monthsDescription: Early response was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 1 week.
Measure: Early response Time: 7 daysDescription: Initial treatment was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 1 month.
Measure: Initial response Time: 1 monthDescription: Durable response was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 6 months.
Measure: Durable response Time: 6 monthsDescription: The time to achieve platelet count ≥ 30×10^9/L and at least 2-fold increase of the baseline count and absence of bleeding since start of treatment.
Measure: TOR (time to response) Time: 6 monthsDescription: The duration of achieve platelet count ≥ 30×10^9/L and at least 2-fold increase of the baseline count and absence of bleeding since start of treatment.
Measure: DOR (duration of response) Time: 6 monthsDescription: All patients were assessed for safety every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Measure: Treatments associated adverse events Time: 6 monthsDescription: Changes of bleeding after treatment. Bleeding was defined in accordance with the WHO bleeding scale (0, no bleeding; 1, petechiae; 2, mild blood loss; 3, gross blood loss; and 4, debilitating blood loss).
Measure: Reduction in bleeding symptoms Time: 6 monthsThis is a prospective, single-arm study to investigate the efficacy and safety of the combination of fixed low-dose eltrombopag plus recombinant human thrombopoietin (rhTPO) as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients during the COVID-19 pandemic.
Description: A complete response (CR) was defined as a sustained (≥ 3 months) platelet count ≥ 100×10^9/L.
Measure: Complete response Time: 6 weeksDescription: A response (R) was defined as a sustained (≥ 3 months) platelet count ≥ 30×10^9/L without recurrence of thrombocytopenia.
Measure: Response Time: 6 weeksDescription: No response (NR) was defined as platelet count < 30 × 10^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart.
Measure: No response Time: 6 weeksDescription: A relapses was defined as platelet count falls below 30×10^9/L or bleeding accrues after achieving R or CR.
Measure: Relapses Time: 6 weeksDescription: Early response was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 1 week.
Measure: Early response Time: 7 daysDescription: Initial treatment was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 1 month.
Measure: Initial response Time: 1 monthDescription: The time to achieve platelet count ≥ 30×10^9/L and at least 2-fold increase of the baseline count and absence of bleeding since start of treatment.
Measure: TOR (time to response) Time: 6 weeksDescription: The duration of achieve platelet count ≥ 30×10^9/L and at least 2-fold increase of the baseline count and absence of bleeding since start of treatment.
Measure: DOR (duration of response) Time: 6 weeksDescription: All patients were assessed for safety every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Measure: Treatments associated adverse events Time: 6 weeksDescription: Changes of bleeding after treatment. Bleeding was defined in accordance with the WHO bleeding scale (0, no bleeding; 1, petechiae; 2, mild blood loss; 3, gross blood loss; and 4, debilitating blood loss).
Measure: Reduction in bleeding symptoms Time: 6 weeksThis is a randomized, two-arm crossover study. Subjects will undergo a placebo and rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).
Description: Mean difference in area under the curve (AUC) between rosuvastatin 10mg + placebo versus rosuvastatin 10mg + eltrombopag 75mg
Measure: Composite of pharmacokinetics of co-administration of rosuvastatin and eltrombopag in healthy volunteers. Time: 24 and 72 hoursDescription: Mean difference in Cmax between rosuvastatin 10mg + placebo versus rosuvastatin 10mg + eltrombopag 75mg
Measure: Composite of pharmacokinetics of co-administration of rosuvastatin and eltrombopag in healthy volunteers. Time: 24 hourDescription: Mean difference in BCRP biomarker Cmax between rosuvastatin 10mg + placebo vs rosuvastatin 10mg + eltrombopag 75mg
Measure: Composite of BCRP biomarkers of co-administration of rosuvastatin and eltrombopag in healthy volunteers. Time: 24 and 72 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports